Measles virus 11234 Measles virus (MV) has two envelope glycoproteins, the haemagglutinin (H) and fusion proteins, which are responsible for attachment and membrane fusion, respectively. Human signalling lymphocyte activation molecule (SLAM; also called CD150), a membrane glycoprotein of the immunoglobulin superfamily, acts as a cellular receptor for MV. SLAM is expressed on immature thymocytes, activated lymphocytes, macrophages and dendritic cells. It regulates production of interleukin (IL)-4 and IL-13 by CD4+ T cells, as well as production of IL-12, tumour necrosis factor alpha and nitric oxide by macrophages. The distribution of SLAM is in accord with the lymphotropism and immunosuppressive nature of MV (Yanagi et al., 2006). Measles Although innate responses probably contribute to control of virus replication during the incubation period, the onset of clinically apparent disease coincides with the appearance of MV-specific adaptive humoral and cellular immune responses. Antibody can protect from MV infection and may contribute to recovery from infection. Antibody is sufficient for protection because infants are protected by maternal antibody and passive transfer of immune serum can modify or interfere with measles vaccination and can partially protect children from measles after exposure. The best correlate of protection from infection is the level of neutralizing antibody. In infants, the level of maternal antibody correlates with failure of the humoral response to vaccination (Griffin et al., 2008). Humans are the only known natural host of measles, although the virus can infect some non-human primate species (Wiki: Measles). Measles virus is a negative strand RNA virus in the Morbillivirus genus of the Paramyxoviridae family. The virus was first isolated in 1954. Measles virus causes measles, a highly infectious disease of humans spread by the respiratory route and characterized by fever and rash. Important complications include secondary infections associated with MV-induced immune suppression and the neurological disease post-infectious encephalomyelitis (Griffin et al., 2008). Baboon Papio cynocephalus 9556 Bank vole Clethrionomys glareolus 447135 Bear Ursus americanus 9643 Birds Passeroidea 175121 Brown Trout Salmo trutta 8032 Buffalo Bison bison 9901 Carnivores Vulpes 9625 Cat Felis catus 9685 Catfishes Siluriformes 7995 Cattle Bos taurus 9913 Chicken Gallus gallus 9031 Chimpanzee Pan troglodytes 9598 chinchillas Chinchillidae 10150 Copper Pheasant Syrmaticus soemmerringii 9067 Deer Cervus elaphus 9860 Deer mouse Peromyscus maniculatus 10042 Dog Canis familiaris 9615 Ducks Anas 8835 Ferret Mustela putorius furo 9669 Fish Hyperotreti 117565 Gerbil Gerbillina 10045 Goat Capra hircus 9925 Gray wolf Canis lupus 9612 Guinea pig Cavia porcellus 10141 Hamster Mesocricetus auratus 10036 Horse Equus caballus 9796 Human Homo sapiens 9606 Macaque Macaca fascicularis 9541 Mongolian Gerbil Meriones unguiculatus 10047 Monkey Platyrrhini 9479 Mouse Mus musculus 10090 None None Parrot Psittacidae 9224 Pig Sus scrofa 9823 Rabbit Oryctolagus cuniculus 9986 Rainbow trout Oncorhynchus mykiss 8022 Rat Rattus 10114 Raven Corvus corax 56781 sei whale Balaenoptera borealis 9768 Sheep Ovis aries 9940 Squirrel Spermophilus richardsonii 37591 Tree shrew Tupaiidae 9393 Trouts, salmons & chars Salmoninae 504568 Turkey Meleagris gallopavo 9103 Vole Microtus ochrogaster 79684 Water buffalo Bubalus bubalis 391902 ALVAC-MV-HA/F VO_0004741 Recombinant vector vaccine Research Intramuscular injection (i.m.) Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992). Intramuscular injection (i.m.) Recombinant vector construction Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992). Recombinant vector construction Canarypox virus (CPV) recombinants expressing the hemagglutinin (HA) and fusion (F) glycoproteins of measles virus (MV) (Taylor et al., 1992). Vaccinate the dogs with recombinant vaccine (Taylor et al., 1992). VO_0003057 The recombinants elicited a protective immune response. The level of MV neutralizing antibodies and the level of protection induced against CDV challenge achieved by the host-restricted CPV vector were equivalent to that obtained by vaccinia virus vectors expressing the same MV antigens (Taylor et al., 1992). Lethal does of canine distember virus (CDV) (Taylor et al., 1992). Canine Distemper-Adenovirus Type 2-Measles-Parainfluenza Modified Live Virus Vaccine (USDA: 1341.20) Pfizer, Inc. VO_0002095 Live, attenuated vaccine Licensed USA Canine Distemper-Measles Modified Live Virus Vaccine (USDA: 1351.20) Pfizer, Inc. VO_0002096 Live, attenuated vaccine Licensed USA Eolarix Eolarix GlaxoSmithKline VO_0010712 Live, attenuated vaccine Licensed Subcutaneous injection Canada Products: Live virus. Other components: Human albumin, Lactose, Dextran. 2 to 8°C (36 to 46°F) or colder. Do not freeze. Subcutaneous injection licensed Measles human vaccine Generic Unknown VO_0000654 Live, attenuated vaccine Licensed A generic representation of vaccines utilized to prevent measles infection in humans, most commonly using live, attenuated strains of the measles virus to induce protective immunity. These vaccines have been historically licensed and widely used for measles prevention. M-M-R II M-M-R II Merck Frosst VO_0000069 Live vaccine Licensed Subcutaneous injection Canada Products: Live virus. Other components: Bovine serum, Glutamate, Yeast-derived, recombinant Human albumin, Residual protein, from cell culture, Sorbitol, Sucrose. Subcutaneous injection M-M-RVaxPro Measles and Mumps Virus Vaccine, Live M-M-RVaxPro Merck and Co., Inc. Live, attenuated vaccine Licensed Intramuscular injection (i.m.) USA M-M-RvaxPro is a lyophilised live virus vaccine manufactured with recombinant human albumin for vaccination against measles, mumps and rubella. (Gillet et al., 2009) Both vaccines were stored at 2°C to 8°C and reconstituted with sterile water for injections immediately before use. (Gillet et al., 2009) A lyophilised preparation of the live Oka strain varicella virus, with a potency of not less than 1350 plaque-forming units. Both vaccines were stored at 2°C to 8°C and reconstituted with sterile water for injections immediately before use. (Gillet et al., 2009) Intramuscular injection (i.m.) Measles Virus vaccine VEE/SIN-H VO_0004187 Recombinant vector vaccine Licensed Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles [Ref1175:Pan et al., 2010]. Intradermal injection (i.d.) Intradermal injection (i.d.) Recombinant vector construction Rhesus macaques Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 10^8 VEE/SIN-H particles or 108 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010) Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010). For MV challenge, 10^4 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010). Measles Virus vaccine VEE/SIN-H+F VO_0011422 Recombinant vector vaccine Research chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles [Ref1175:Pan et al., 2010]. Intradermal injection (i.d.) Intradermal injection (i.d.) Recombinant protein preparation Recombinant protein preparation Rhesus macaques Juvenile rhesus macaques were vaccinated with a single intradermal (i.d.) injection of 10^8 VEE/SIN-H particles or 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles (VEE/SIN-H+F). Two juvenile monkeys were vaccinated with one dose of 5,000 PFU of the Moraten strain of LAV intramuscularly (i.m.). Two juvenile monkeys were vaccinated with three doses of 0.5 ml of FIMV i.m. at 0, 4, and 8 weeks. Three infant rhesus macaques were immunized i.d. with 10^8 VEE/SIN-H particles plus 3 x 10^6 VEE/SIN-F particles and boosted 2 months later (Pan et al., 2010). Neutralizing antibody remained above the protective level for more than 1 year after vaccination with VEE/SIN-H, VEE/SIN-H+F, or LAV. When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia, while FIMV-vaccinated monkeys were not (Pan et al., 2010). For MV challenge, 10^4 tissue culture 50% infectious doses (TCID50) of the Bilthoven strain of MV were instilled intratracheally into anesthetized animals 12 to 17 months after vaccination. Monkeys were shaved and monitored frequently for development of a rash (Pan et al., 2010). VEE/SIN-H+F vaccinated rhesus macaques showed a significant increase in IFN-gamma producing cells in blood 1 to 2 weeks after vaccination as compared to the current live attenuated virus vaccine (LAV). The significant increase came after stimulation with the measles H-peptide (Pan et al., 2010). Measles Virus Vaccine VVM VO_0011537 Recombinant vector vaccine Research Vaccinia Virus [Ref1177:Brinckmann et al., 1991]. Intraperitoneal injection (i.p.) Intraperitoneal injection (i.p.) Recombinant vector construction Lewis To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10^7 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991). Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991). Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10^4 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991). Measles Virus Vaccine VVN VO_0011535 Recombinant vector vaccine Research Vaccinia virus [Ref1177:Brinckmann et al., 1991]. Intraperitoneal injection (i.p.) Intraperitoneal injection (i.p.) Recombinant vector construction Lewis To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10^7 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991). Rats immunized with recombinant VVN survived a MV challenge infection (Brinckmann et al., 1991). Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10^4 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991). Measles Virus Vaccine VVP VO_0011536 Recombinant vector vaccine Research Vaccinia virus [Ref1177:Brinckmann et al., 1991]. Intraperitoneal injection (i.p.) Intraperitoneal injection (i.p.) Recombinant vector construction Lewis To determine the protective effect of individual measles virus (MV) proteins, 2- to 3-week-old suckling rats were immunized either once, twice or three times at 5 to 7 day intervals by i.p. injections of 10^7 p.f.u, of recombinant vaccinia virus (VV) expressing individual structural proteins or VV-wt (Brinckmann et al., 1991). Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge (Brinckmann et al., 1991). Three to 5 days after the last recombinant VV injection, the animals were challenged by intracerebral (i.c.) infection with the neurotropic rat brain-adapted MV strain CAM/RBH (0.5 × 10^4 to 8 x 10 ~ TCID50) (Brinckmann et al., 1991). Priorix Priorix GlaxoSmithKline VO_0010734 Live, attenuated vaccine Licensed Subcutaneous injection Canada Products: Live virus. Other components: Lactose. Store at at 2 to 8°C. Subcutaneous injection Priorix-Tetra Priorix-Tetra GlaxoSmithKline VO_0010735 Live, attenuated vaccine Licensed Subcutaneous injection Canada Products: Live virus. Other components: Lactose. Store at at 2 to 8°C. Do not freeze (GSK: Priorix-Tetra). Subcutaneous injection ProQuad Measles, Mumps, Rubella and Varicella Virus Vaccine Live ProQuad Merck & Co, Inc. VO_0000091 Live, attenuated vaccine Licensed Intramuscular injection (i.m.) USA (License #0002) ProQuad is a sterile lyophilized preparation of (1) the components of M-M-R*II (Measles, Mumps and Rubella Virus Vaccine Live): Measles Virus Vaccine Live, a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts; and (2) Varicella Virus Vaccine Live (Oka/Merck) refrigerator-stable formulation, the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells (FDA: ProQuad). maintained at a temperature of 2° to 8°C (36° to 46°F) or colder. propagated in chick embryo cell culture. Intramuscular injection (i.m.) According to clinical trials, there were high levels of antibodies in 98.9% of those vaccinated after a single dose of Proquad (FDA: ProQuad). Side effects of vaccination include: injection site reactions, fever, irritability and diarrhea. F fusion protein Measles morbillivirus VO_0011167 1489800 9626950 MeVgp4 AB016162 NP_056922 11234 4875 7246 + mRNA 8.55 55859.92 550 additional G inserted at 2499:V >NC_001498.1:4875-7246 Measles virus, complete genome AGGGCCAAGGAACACACACACTCGACAGAACCCAGACCCCGGCCCGCGGCACCGCGCCCCCACCCCCCGA AAACCAGAGGGAGCCCCCAACCAAACCCGCCGGCCCCCCCGGTGCCCACAGGTAGGCACACCAACCCCCG ACCAGACCCAGCACCCAGCCACCGACAATCCAAGACGGGGGGCCCCCCCCAAAAAAAGGCCCCCAGGGGC CGACAGCCAGCATCGCGAGGAAGCACACCCACCCCACACACGACCACGGCAACCGAACCAGAGTCCAGAC CACCCTGGGCCACCAGCTCCCAGACTCGGCCATCACCCCGCAAAAAGGAAAGGCCACAACCCGCGCACCC CAGCCCCGATCCGGCGGGCAGCCACTCAACCCGAACCAGCACCCAAGAGCGATCCCTGGGGGACCCCCAA ACCGCAAAAGACATCAGTATCCCACAGCCTCTCCAAGTCCCCCGGTCTCCTCCTCTTCTCGAAGGGACCA AAAGATCAATCCACCACATCCGACGACACTCAATTCCCCACCCCCAAAGGAGACACCGGGAATCCCAGAA TCAAGACTCATCCAGTGTCCATCATGGGTCTCAAGGTGAACGTCTCTGCCATATTCATGGCAGTACTGTT AACTCTCCAAACACCCACCGGTCAAATCCATTGGGGCAATCTCTCTAAGATAGGGGTGGTAGGGATAGGA AGTGCAAGCTACAAAGTTATGACTCGTTCCAGCCATCAATCATTGGTCATAAAATTAATGCCCAATATAA CTCTCCTCAATAACTGCACGAGGGTAGAGATCGCAGAATACAGGAGACTACTGAGAACAGTTTTGGAACC AATTAGAGATGCACTTAATGCAATGACCCAGAATATAAGACCGGTTCAGAGTGTAGCTTCAAGTAGGAGA CACAAGAGATTTGCGGGAGTTGTCCTGGCAGGTGCGGCCCTAGGCGTTGCCACAGCTGCTCAGATAACAG CCGGCATTGCACTTCACCAGTCCATGCTGAACTCTCAAGCCATCGACAATCTGAGAGCAAGCCTGGAAAC TACTAATCAGGCAATTGAGGCAATCAGACAAGCAGGGCAGGAGATGATATTGGCTGTTCAGGGTGTCCAA GACTACATCAATAATGAGCTGATACCGTCTATGAACCAACTATCTTGTGATTTAATCGGCCAGAAGCTAG GGCTCAAATTGCTCAGATACTATACAGAAATCCTGTCATTATTTGGCCCCAGCTTACGGGACCCCATATC TGCGGAGATATCCATCCAGGCTTTGAGCTATGCGCTTGGAGGAGATATCAATAAGGTATTAGAAAAGCTC GGATACAGTGGAGGTGATTTACTGGGCATCTTAGAGAGCAGAGGAATAAAGGCCCGGATAACTCACGTCG ACACAGAGTCCTACTTCATTGTACTCAGTATAGCCTATCCGACGCTGTCCGAGATTAAGGGGGTGATTGT CCACCGGCTAGAGGGGGTCTCGTACAATATAGGCTCTCAAGAGTGGTATACCACTGTGCCCAAGTATGTT GCAACCCAAGGGTACCTTATCTCGAATTTTGATGAGTCATCGTGTACTTTCATGCCAGAGGGGACTGTGT GCAGCCAAAATGCCTTGTACCCGATGAGTCCTCTGCTCCAAGAATGCCTCCGGGGGTCCACCAAGTCCTG TGCTCGTACACTCGTATCCGGGTCTTTTGGGAACCGGTTCATTTTATCACAAGGGAACCTAATAGCCAAT TGTGCATCAATCCTCTGCAAGTGTTACACAACAGGAACGATCATTAATCAAGACCCTGACAAGATCCTAA CATACATTGCTGCCGATCACTGCCCGGTGGTCGAGGTGAACGGTGTGACCATCCAAGTCGGGAGCAGGAG GTATCCGGACGCGGTGTACCTGCACAGAATTGACCTCGGTCCTCCCATATCATTGGAGAGGTTGGACGTA GGGACAAATCTGGGGAATGCAATTGCTAAGTTGGAGGATGCCAAGGAATTGTTGGAGTCATCGGACCAGA TATTGAGGAGTATGAAAGGTTTATCGAGCACTAGCATAGTTTACATCCTGATTGCAGTGTGTCTTGGAGG GTTGATAGGGATCCCCGCTTTAATATGTTGCTGCAGGGGGCGCTGTAACAAAAAGGGAGAACAAGTTGGT ATGTCAAGACCAGGCCTAAAGCCTGATCTTACAGGGACATCAAAATCCTATGTAAGGTCGCTCTGATCCT CTACAACTCTTGAAACACAGATTTCCCACAAGTCTCCTCTTCGTCATCAAGCAACCACCGCATCCAGCAT CAAGCCCACCTGAAATTGTCTCCGGCTTCCCTCTGGCCGAACGATATCGGTAGTTAATTAAA >NP_056922.1 fusion protein [Measles morbillivirus] MGLKVNVSAIFMAVLLTLQTPTGQIHWGNLSKIGVVGIGSASYKVMTRSSHQSLVIKLMPNITLLNNCTR VEIAEYRRLLRTVLEPIRDALNAMTQNIRPVQSVASSRRHKRFAGVVLAGAALGVATAAQITAGIALHQS MLNSQAIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELIPSMNQLSCDLIGQKLGLKLLRYY TEILSLFGPSLRDPISAEISIQALSYALGGDINKVLEKLGYSGGDLLGILESRGIKARITHVDTESYFIV LSIAYPTLSEIKGVIVHRLEGVSYNIGSQEWYTTVPKYVATQGYLISNFDESSCTFMPEGTVCSQNALYP MSPLLQECLRGSTKSCARTLVSGSFGNRFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAADHC PVVEVNGVTIQVGSRRYPDAVYLHRIDLGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQILRSMKGL SSTSIVYILIAVCLGGLIGIPALICCCRGRCNKKGEQVGMSRPGLKPDLTGTSKSYVRSL Protective antigen Mice vaccinated with a vaccinia virus recombinant encoding the fusion protein of Measles virus developed measles neutralizing antibodies. The mice also resisted a normally lethal intracerebral inoculation of a cell-associated measles virus subacute sclerosing panencephalitis strain [Ref1314:Drillien et al., 1988]. H hemagglutinin protein Measles morbillivirus VO_0011166 1489801 9626951 MeVgp5 AB016162 NP_056923 2RKC 11234 7250 9207 + mRNA 7.85 64311.39 617 >NC_001498.1:7250-9207 Measles virus, complete genome TAGGGTGCAAGATCATCCACAATGTCACCACAACGAGACCGAATAAATGCCTTCTACAAAGACAACCCAC ATCCTAAGGGAAGTAGGATAGTTATTAACAGAGAACATCTTATGATTGATAGACCTTATGTTTTGCTGGC TGTTCTATTCGTCATGTTTCTGAGCTTGATCGGGTTGCTAGCCATTGCAGGCATTAGACTCCATCGTGCA GCCATCTACACCGCAGAGATCCATAAGAGCCTCAGCACCAATCTAGATGTAACTAACTCGATCGAGCATC AGGTCAAGGACGTGCTGACACCACTCTTCAAGATCATTGGTGATGAAGTGGGCCTGAGGACACCTCAGAG ATTCACTGACCTAGTGAAATTCATCTCTGACAAAATTAAATTCCTTAATCCGGATAGGGAGTACGACTTC AGAGATCTCACTTGGTGTATCAACCCGCCAGAGAGAATCAAATTGGATTATGATCAATACTGTGCAGATG TGGCTGCTGAAGAACTCATGAATGCATTGGTGAACTCAACTCTACTGGAGGCCAGGGCAACCAATCAGTT CCTAGCTGTCTCAAAGGGAAACTGCTCAGGGCCCACTACAATCAGAGGTCAATTCTCAAACATGTCGCTG TCCCTGTTGGACTTGTATTTAAGTCGAGGTTACAATGTGTCATCTATAGTCACTATGACATCCCAGGGAA TGTACGGGGGAACTTACCTAGTGGGAAAGCCTAATCTGAGCAGTAAAGGGTCAGAGTTGTCACAACTGAG CATGCACCGAGTGTTTGAAGTAGGGGTTATCAGAAATCCGGGTTTGGGGGCTCCGGTGTTCCATATGACA AACTATTTTGAGCAACCAGTCAGTAATGATTTCAGCAACTGCATGGTGGCTTTGGGGGAGCTTAAATTCG CAGCCCTCTGTCACAGGGAAGATTCTATCACAATTCCCTATCAGGGGTCAGGGAAAGGTGTCAGCTTCCA GCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGACATGCGATCCTGGGTCCCCCTATCAACGGATGAT CCAGTGATAGATAGGCTTTACCTCTCATCTCACAGAGGTGTTATCGCTGACAATCAAGCAAAATGGGCTG TCCCGACAACACGGACAGATGACAAGTTGCGAATGGAGACATGCTTCCAGCAGGCGTGTAAGGGTAAAAA CCAAGCACTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAACAGGATTCCTTCATACGGGGTCTTG TCTGTTAATCTGAGTCTGACAGTTGAGCTTAAAATCAAAATTGCTTCAGGATTCGGGCCATTGATCACAC ACGGTTCAGGGATGGACCTATACAAAACCAACCACAACAATGTGTATTGGCTGACTATCCCGCCAATGAA GAACCTAGCCTTAGGTGTAATCAACACATTGGAGTGGATACCGAGATTCAAGGTTAGTCCCAACCTCTTC ACTGTTCCAATCAAGGAAGCAGGCGAGGACTGCCATGCCCCAACATACCTACCTGCGGAGGTGGATGGTG ATGTCAAACTCAGTTCCAATCTGGTAATTCTACCTGGTCAGGATCTCCAATATGTTTTGGCAACCTACGA TACTTCCAGGGTTGAACATGCTGTGGTTTATTATGTTTACAGCCCAAGCCGCTCATTTTCTTACTTTTAT CCTTTTAGGTTGCCTATAAAGGGGGTCCCAATCGAATTACAAGTGGAATGCTTCACATGGGACAAAAAAC TCTGGTGCCGTCACTTCTGTGTGCTTGCGGACTCAGAATCTGGTGGACATATCACTCACTCTGGGATGGT GGGCATGGGAGTCAGCTGCACAGTCACTCGGGAAGATGGAACCAATCGCAGATAGGGCTGCCAGTGAACC GATCACATGATGTCACCCAGACATCAGGCATACCCACTAGTGTGAAATAGACATCAGAATTAAGAAAA >NP_056923.1 hemagglutinin protein [Measles morbillivirus] MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRLHRAAIYTAEI HKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKFISDKIKFLNPDREYDFRDLTWCI NPPERIKLDYDQYCADVAAEELMNALVNSTLLEARATNQFLAVSKGNCSGPTTIRGQFSNMSLSLLDLYL SRGYNVSSIVTMTSQGMYGGTYLVGKPNLSSKGSELSQLSMHRVFEVGVIRNPGLGAPVFHMTNYFEQPV SNDFSNCMVALGELKFAALCHREDSITIPYQGSGKGVSFQLVKLGVWKSPTDMRSWVPLSTDDPVIDRLY LSSHRGVIADNQAKWAVPTTRTDDKLRMETCFQQACKGKNQALCENPEWAPLKDNRIPSYGVLSVNLSLT VELKIKIASGFGPLITHGSGMDLYKTNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPNLFTVPIKEA GEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYFYPFRLPIK GVPIELQVECFTWDKKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDGTNRR Protective antigen Chimeric Venezuelan equine encephalitis/Sindbis virus (VEE/SIN) replicon particles were used to express the hemagglutinin (H) and fusion (F) proteins of measles virus (MV). When challenged with wild-type MV 12 to 17 months after vaccination, all vaccinated juvenile and infant monkeys vaccinated with VEE/SIN-H, VEE/SIN-H+F, and LAV were protected from rash and viremia [Ref1175:Pan et al., 2010]. IFNG Macaca mulatta 574282 74136365 EGK_03901 CM001263 NP_001028077 9544 11 65143979 65148219 - interferon-gamma 9.92 18339.63 165 Also known as IFN-gamma >gi|109156580:65143979-65148219 Macaca mulatta chromosome 11, Mmul_051212, whole genome shotgun sequence ATTATTGGGATGCTCTTCGACCTCGAAACATCTGACTCCTTTTTCGCTTCCCTATTTTAGCTGCTGGCGA CAGTTCAGCCATCACTTGGATGAGTTCATGTACTGCTTTGCGTTGGACATTTGAGTCAGTTACCTATTGG GAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGGATATTCAGTTAATGGCATGATGGTCA GTGAAAATAAAACTATTCCTTTAAAAAAATGGACCATATTACCTTAATATACAATATTTACTTCTTCAGC AGTTGAGGCTAAAAATTACAATTACATTACTAGTTGTGCAATGATGTGGTGGAGTCCGTCACATATCTTT AAATCTACTCCCATAGAATTCTTGAAATCATATAGTGAAAAGACCCCTGGTGTGGAGTCAATGTAAAAAG GTGGATCTGAATCTCATGCGTGCAATAATTCTGACCTTGAGCCAGCTACTTAACCTTTTGGAACCTCTAT TTTCTCATCTAAAGGAAGAGAAGACTGTTTCTATGACCTCTCTATCATCAATCTACCAATTATATCACTT TATACTTTAGTCTCTCCTGTATGTATCAAACGAGTAACTATAGGTCAATGATTCTCACTGTTGTGCATAG CAGATTAACCTGGAAACCTAATAAAGACCTCAGAGATCCAGGGGCACGAATTGGAAGGACTGTGCCCTGT GCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTTTGAGAACCACTGATCTAGGTTAGGTA CCCTAGAAAACATCAAATCCAAAACAAGTGAAAACTGTAATTTTTAATTTCTCCCAGATTAGATCAGTCT CTCAATTTCCATAATAGGTTTTAAAATAACCACCAATCATATTTATATATGGCTTACTGATATATAAAGT TTAAAATTAGGAATTGCAACAACTTTTTCAGTACCCTACCTTCTAGGCCAGCAAATTGAACTACTTGCAT TTCCTCACTCTAACTAATAGGGCCATTTAGGTGATTTCATTCTTCCTAAAATGTGGACCATTTACTTTCC TCTTGACTCTGCCATTATATTTTTTCTAATCTTGGGAACACTATGGCTACCTCGCCACATTTCTGAGGAT GGCTGGGGGATTACAGGCTACAGAGCTAATTATGAAAGGGCATAACATACCTCAGCTTAGCAACTGAGCC AAAGAGAACAATAATTAATAGAGCTCACTCAAGATTGCCCATCAAGAAACAGGAGGTTTGTAGCTTCCAG AAGGAAGAAACCCACAGATTTTTTTTTCACTTTTTTAAGGCCCAGTTCCTGCGGAGTAGAAAAAGTTTTC TACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAGTGTTCAAATCATCACCAAGAAACTAAGAG ACTTATCCAGGACGGAACAGTAAGCCAGGGGCACCACTGGGTTGGTGGCAAGTGCTGAGTGTCTAGTTTC TAACCAAAGGAGACCTGTTGCCATGTCCCTCCTTTCAGTTTCTGGGGGTTCACATGAGAGGAGTGAGAGG CAGGCCCGGCAATAGTGAAAGCTGAGCACAAATCCTAAGAGCACAAATGCCAGCTTGAGCTCTCATTTGA GCCCATTTATATCAAAGCCAATCCCAAAGGAATCTAGAGGTCTTTGTCTTCTAGATAAAATTTTGAAAAA CGTGTTTTGTCTTTATGCCTCAATGTTATCTTTCTGTTTATAGAAGGCATAATTTAAAGATAATTTAAAG ATACAAGTTCATGAGGTATGACTTAGGAGTCTAAGGAGTTCTCCAGCTGAGATATTCTGAAAGTTGATAG AGACTTGATAGAACAATGTTTTCATAAGCTATAAATTCTACCTATTTTTCCCTAAAAACAAACAGCAACC ATTCTTGCTTCTAATTAGGCAGTACAATCTGATAGGTTGGCTAGAGAATTGCAGTGGGGTGCACTGGTAC CTACTCAAAGGCTGTAGCTTTCTTCTATCTCATTCTCATTTTCTATTCTTGGCATTGTAGAGTTTTGGAG CAAAGAATGTCATCAAACTTATGCAGTGAACCTAACAGTTTCCTTTTAAGATGAGGGCACTGAGCCCCAG CCAGCCATGTGATTCATCACAGTTCCCTGGTGGCTGAGATGGGAGGAGAACACACATCTTCTCAGCTCCT CCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAAGTAAGAGAATTTCCATCATATGAGCAAA GGACAATGAGAGAATTGCTTCTCAGTACTCCCCACTACTTCCTCACCTACTTCCTCTTCATTGGATTTGT CAATTCACCTGTCTTTACACAATAGTTACAATGCCAGCACTTTTCCTACATTACATACTTCAGTGATTCC CATACTGGCTTTGCAAAGTCATCCAAACACAAATAGAATTAGTAAGAGTTTCAGCTACGGGTTGAGTTCA TAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCTGGAGAACAAATGCTTTGCAAGACCTTCCGCA ATGAAACCAAAGAAAGAATTTAAAGAGCCTTACCGAATAATTGGTCAGCTTTTCAAAGTCATCCCGTTTC TTTTTGTTGCTATTGAAAAACTTGACATTAATGTCTTCCTTGATGGTCTCCACACTCTTTTGGATCCTCT GGTCATCTTTGAAGTTTTTAAAAAGTTTGAAGTAAAAGGAGACAATTTGGCTCTGCATTATTTTTCTGTC ACTCTCCTTGGAAGGAAAGAACACAAACAGAGGATGATGTGTATTTATCCATCAGAAAGCAAGCAACAGG AAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCCAATTCCTCAAGATGTCTAAGAAAAGAGTTCC ATTATCTGCTACATCTGGATCACCTGCATTCTGGGGGAAAAAAAAGGGTTTACAATTAGCCCATAAATTG TCTTAAAAATATATTTCAAGTTTCATTAAACTCAGATGTGACAATATTCACTGATTTCCTTTTCAATTCT TCTGCTTAGTTCTAACAATAAGTGTTCACAAAATGTTTATGTGAGATATAGCCAAAGACTACTATGCTCT TTTAGCTTTTTTATTTTCCAACATAACCATTAAATTGCAATGTCACAAAGGAGTTAAACAAAGCTGATGA TACTCCAAGGGTCTCAAAAACTATAGTAGGCTAAAGAAAGTATTTTCAAGCTAGGCTAAAAAATACAGAA CAAAAAACAGCAAAGCCACCCCACTATAAAATACTGCCCCCCAATGGCACAGGTTTCTATTACATCTACT ATGCCTTCCTGTAGGGTATTATGTCAACTTTAAAAGATAGTTCCAAACGTGTGCGTGCGTGTGTGTGTGT GTGTGTGTGTGTGGTCTGATTTTGTGTTGTAGGAATAAAATTAATTGTGAATGTCTGAATATTAGTATGA CAGCTATAATTATAACTAAGTTTTAAATAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCA TCAATAAAATTTTAAAAGAAACTCAAAAAACTCACTTAAAATTTTTAAACATTCCATAGCCAGAATCATA ATTCCTACAAAATCCCAGTGAGCAACTAAGTTCAGGAGTAATTCACAAGGAATATAGATAGAGCAGCAGA ATGTTGAAATAACTTTTTGGAGAAAATCACCTATCAGTGATTTTTTTTAAGCCAAAACTTTAAGGACCTT TTTTACTTTAATTTGTAAACGTTTCCTATTAACTTTTGAATGCTAATCTTGACCTTAGAGTCTGAGAAGT CAAAAACTAATAGCCAATCATTTTTTTCAATATGCATACTCCTTGACTTATCACATCTGAATGAGTTCTC ACCACAAAATTATTAACATCATTATGCTTCATATCCATATTATGCCCATCTTTGGGAAGATTCATAAATC CCTTTTAAGTCTCTATACAAACTGAGCAGAAGGTTAAAACAATATCTAGATTATGTAGTCAAGAAACTCA TCCAGTCAATAATTAACAAAATAAAACCAGATCTCAAAATGACTGCGTACGAGAGGACAGTCTATCAGAG ATGCTACAGCAAGTCAATATTCAGACATTTTCAACCACAAAAAAGTACTATTAAAAAGCCATACTTACAA AATATTTCTTAAGGTTTTCTGCTTCTTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAAC AATGCAGAGCTGAAAAGCCAAGATATAACTTGTGTATTTCA >gi|74136365|ref|NP_001028077.1| interferon gamma precursor [Macaca mulatta] MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDPDVADNGTLFLDILRNWKEESDRKIMQS QIVSFYFKLFKNFKDDQRIQKSVETIKEDINVKFFNSNKKKRDDFEKLTNYSVTDSNVQRKAVHELIQVM AELSPAAKIGKRKRSQMFRGRRASQ Vaximmutor M matrix protein Measles morbillivirus VO_0011170 1489803 9626949 MeVgp3 AB002686 NP_056921 11234 3405 4871 + mRNA 9.25 35032.9 335 >NC_001498.1:3405-4871 Measles virus, complete genome TAGGAGCAAAGTGATTGCCTCCTAAGTTCCACAATGACAGAGATCTACGATTTCGACAAGTCGGCATGGG ACATCAAAGGGTCGATCGCTCCGATACAACCTACCACCTACAGTGATGGCAGGCTGGTGCCCCAGGTCAG AGTCATAGATCCTGGTCTAGGTGATAGGAAGGATGAATGCTTTATGTACATGTTTCTGCTGGGGGTTGTT GAGGACAGCGATCCCCTAGGGCCTCCAATCGGGCGAGCATTCGGGTCCCTGCCCTTAGGTGTTGGTAGAT CCACAGCAAAACCCGAGGAACTCCTCAAAGAGGCCACTGAGCTTGACATAGTTGTTAGACGTACAGCAGG GCTCAATGAAAAACTGGTGTTCTACAACAACACCCCACTAACCCTCCTCACACCTTGGAGAAAGGTCCTA ACAACAGGGAGTGTCTTCAATGCAAACCAAGTGTGCAATGCGGTTAATCTAATACCGCTGGACACCCCGC AGAGGTTCCGTGTTGTTTATATGAGCATCACCCGTCTTTCGGATAACGGGTATTACACCGTTCCCAGAAG AATGCTGGAATTCAGATCGGTCAATGCAGTGGCCTTCAACCTGCTAGTGACCCTTAGGATTGACAAGGCG ATTGGCCCTGGGAAGATCATCGACAATGCAGAGCAACTTCCTGAGGCAACATTTATGGTCCACATCGGGA ACTTCAGGAGAAAGAAGAGTGAAGTCTACTCTGCCGATTATTGCAAAATGAAAATCGAAAAGATGGGCCT GGTTTTTGCACTTGGTGGGATAGGGGGCACCAGTCTTCACATTAGAAGCACAGGCAAAATGAGCAAGACT CTCCATGCACAACTCGGGTTCAAGAAGACCTTATGTTACCCACTGATGGATATCAATGAAGACCTTAATC GGTTACTCTGGAGGAGCAGATGCAAGATAGTAAGAATCCAGGCAGTTTTGCAGCCATCAGTTCCTCAAGA ATTCCGCATTTACGACGACGTGATCATAAATGATGACCAAGGACTATTCAAAGTTCTGTAGACCGCAGTG CCCAGCAATACCCGAAAACGACCCCCCTCATAATGACAGCCAGAAGGCCCGGACAAAAAAGCCCCCTCCA GAAGACTCCACGGACCAAGCGAGAGGCCAGCCAGCAGCCGACAGCAAGTGTGGACACCAGGCGGCCCAAG CACAGAACAGCCCCGACACAAGGCCACCACCAGCCATCCCAATCTGCGTCCTCCTCGTGGGACCCCCGAG GACCAACCCCGAAGGTCGCTCCGAACACAGACCACCAACCGCATCCCCACAGCTCCCGGGAAAGGAACCC CCAGCAACTGGAAGGCCCCTCCCCCCCTCCCCCAACGCAAGAACCCCACAACCGAACCGCACAAGCGACC GAGGTGACCCAACCGCAGGCATCCGACTCCTTAGACAGATCCTCTCCCCCCGGCATACTAAACAAAA >NP_056921.1 matrix protein [Measles morbillivirus] MTEIYDFDKSAWDIKGSIAPIQPTTYSDGRLVPQVRVIDPGLGDRKDECFMYMFLLGVVEDSDPLGPPIG RAFGSLPLGVGRSTAKPEELLKEATELDIVVRRTAGLNEKLVFYNNTPLTLLTPWRKVLTTGSVFNANQV CNAVNLIPLDTPQRFRVVYMSITRLSDNGYYTVPRRMLEFRSVNAVAFNLLVTLRIDKAIGPGKIIDNAE QLPEATFMVHIGNFRRKKSEVYSADYCKMKIEKMGLVFALGGIGGTSLHIRSTGKMSKTLHAQLGFKKTL CYPLMDINEDLNRLLWRSRCKIVRIQAVLQPSVPQEFRIYDDVIINDDQGLFKVL Protective antigen Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVM (Matrix Protein) -immunized rats were partially protected from MV challenge [Ref1177:Brinckmann et al., 1991]. N nucleocapsid protein Measles morbillivirus VO_0011168 1489804 9626946 MeVgp1 AB016162 NP_056918 11234 55 1743 + mRNA 4.86 55436.53 525 >NC_001498.1:55-1743 Measles virus, complete genome TAGGATTCAAGATCCTATTATCAGGGACAAGAGCAGGATTAGGGATATCCGAGATGGCCACACTTTTGAG GAGCTTAGCATTGTTCAAAAGAAACAAGGACAAACCACCCATTACATCAGGATCCGGTGGAGCCATCAGA GGAATCAAACACATTATTATAGTACCAATTCCTGGAGATTCCTCAATTACCACTCGATCCAGACTACTGG ACCGGTTGGTCAGGTTAATTGGAAACCCGGATGTGAGCGGGCCCAAACTAACAGGGGCACTAATAGGTAT ATTATCCTTATTTGTGGAGTCTCCAGGTCAATTGATTCAGAGGATCACCGATGACCCTGACGTTAGCATC AGGCTGTTAGAGGTTGTTCAGAGTGACCAGTCACAATCTGGCCTTACCTTCGCATCAAGAGGTACCAACA TGGAGGATGAGGCGGACCAATACTTTTCACATGATGATCCAAGCAGTAGTGATCAATCCAGGTCCGGATG GTTCGAGAACAAGGAAATCTCAGATATTGAAGTGCAAGACCCTGAGGGATTCAACATGATTCTGGGTACC ATTCTAGCCCAGATCTGGGTCTTGCTCGCAAAGGCGGTTACGGCCCCAGACACGGCAGCTGATTCGGAGC TAAGAAGGTGGATAAAGTACACCCAACAAAGAAGGGTAGTTGGTGAATTTAGATTGGAGAGAAAATGGTT GGATGTGGTGAGGAACAGGATTGCCGAGGACCTCTCTTTACGCCGATTCATGGTGGCTCTAATCCTGGAT ATCAAGAGGACACCCGGGAACAAACCTAGGATTGCTGAAATGATATGTGACATTGATACATATATCGTAG AGGCAGGATTAGCCAGTTTTATCCTGACTATTAAGTTTGGGATAGAAACTATGTATCCTGCTCTTGGACT GCATGAATTTGCTGGTGAGTTATCCACACTTGAGTCCTTGATGAATCTTTACCAGCAAATGGGAGAAACT GCACCCTACATGGTAATCCTAGAGAACTCAATTCAGAACAAGTTCAGTGCAGGATCATACCCTCTGCTCT GGAGCTATGCCATGGGAGTAGGAGTGGAACTTGAAAACTCCATGGGAGGTTTGAACTTTGGTCGATCTTA CTTTGATCCAGCATATTTTAGATTAGGGCAAGAGATGGTGAGGAGGTCAGCTGGAAAGGTCAGTTCCACA TTGGCATCCGAACTCGGTATCACTGCCGAGGATGCAAGGCTTGTTTCAGAGATTGCAATGCATACTACTG AGGACAGGATCAGTAGAGCGGTCGGACCCAGACAAGCCCAAGTGTCATTTCTACACGGTGATCAAAGTGA GAATGAGCTACCAGGATTGGGGGGCAAGGAAGATAGGAGGGTCAAACAGGGTCGGGGAGAAGCCAGGGAG AGCTACAGAGAAACCGGGTCCAGCAGAGCAAGTGATGCGAGAGCTGCCCATCCTCCAACCAGCATGCCCC TAGACATTGACACTGCATCGGAGTCAGGCCAAGATCCGCAGGACAGTCGAAGGTCAGCTGACGCCCTGCT CAGGCTGCAAGCCATGGCAGGAATCTTGGAAGAACAAGGCTCAGACACGGACACCCCTAGGGTATACAAT GACAGAGATCTTCTAGACTAGGTGCGAGAGGCCGAGGACCAGAACAACATCCGCCTACCCTCCATCATTG TTATAAAAA >NP_056918.1 nucleocapsid protein [Measles morbillivirus] MATLLRSLALFKRNKDKPPITSGSGGAIRGIKHIIIVPIPGDSSITTRSRLLDRLVRLIGNPDVSGPKLT GALIGILSLFVESPGQLIQRITDDPDVSIRLLEVVQSDQSQSGLTFASRGTNMEDEADQYFSHDDPSSSD QSRSGWFENKEISDIEVQDPEGFNMILGTILAQIWVLLAKAVTAPDTAADSELRRWIKYTQQRRVVGEFR LERKWLDVVRNRIAEDLSLRRFMVALILDIKRTPGNKPRIAEMICDIDTYIVEAGLASFILTIKFGIETM YPALGLHEFAGELSTLESLMNLYQQMGETAPYMVILENSIQNKFSAGSYPLLWSYAMGVGVELENSMGGL NFGRSYFDPAYFRLGQEMVRRSAGKVSSTLASELGITAEDARLVSEIAMHTTEDRISRAVGPRQAQVSFL HGDQSENELPGLGGKEDRRVKQGRGEARESYRETGSSRASDARAAHPPTSMPLDIDTASESGQDPQDSRR SADALLRLQAMAGILEEQGSDTDTPRVYNDRDLLD Protective antigen Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVN (Nucleocapsid Protein) -immunized rats survived a MV challenge infection [Ref1177:Brinckmann et al., 1991]. P phosphoprotein Measles morbillivirus VO_0011169 1489805 9626947 MeVgp2 AB016162 NP_056919 11234 1747 3401 + mRNA 4.73 52011.09 507 RNA editing; co-transcriptional insertion of a non-template G at nt 2499 of the 'P' protein transcript creates V mRNA >NC_001498.1:1747-3401 Measles virus, complete genome TAGGAACCAGGTCCACACAGCCGCCAGCCAACCAACCATCCACTCCCACGACTGGAGCCGATGGCAGAAG AGCAGGCACGCCATGTCAAAAACGGACTGGAATGCATCCGGGCTCTCAAGGCCGAGCCCATCGGCTCACT GGCCGTCGAGGAAGCCATGGCAGCATGGTCAGAAATATCAGACAACCCAGGACAGGACCGAGCCACCTGC AAGGAAGAGGAGGCAGGCAGTTCGGGTCTCAGCAAACCATGCCTCTCAGCAATTGGATCAACTGAAGGCG GTGCACCTCGCATCCGCGGTCAGGGATCTGGAGAAAGCGATGACGACGCTGAAACTTTGGGAATCCCCTC AAGAAATCTCCAGGCATCAAGCACTGGGTTACAGTGTTATCATGTTTATGATCACAGCGGTGAAGCGGTT AAGGGAATCCAAGATGCTGACTCTATCATGGTTCAATCAGGCCTTGATGGTGATAGCACCCTCTCAGGAG GAGACGATGAATCTGAAAACAGCGATGTGGATATTGGCGAACCTGATACCGAGGGATATGCTATCACTGA CCGGGGATCTGCTCCCATCTCTATGGGGTTCAGGGCTTCTGATGTTGAAACTGCAGAAGGAGGGGAGATC CACGAGCTCCTGAAACTCCAATCCAGAGGCAACAACTTTCCGAAGCTTGGGAAAACTCTCAATGTTCCTC CGCCCCCGAACCCCAGTAGGGCCAGCACTTCCGAGACACCCATTAAAAAGGGCACAGACGCGAGATTGGC CTCATTTGGAACGGAGATCGCGTCTTTATTGACAGGTGGTGCAACCCAATGTGCTCGAAAGTCACCCTCG GAACCATCAGGGCCAGGTGCACCTGCGGGGAATGTCCCCGAGTGTGTGAGCAATGCCGCACTGATACAGG AGTGGACACCCGAATCTGGTACCACAATCTCCCCGAGATCCCAGAATAATGAAGAAGGGGGAGACTATTA TGATGATGAGCTGTTCTCCGATGTCCAAGACATCAAAACAGCCTTGGCCAAAATACACGAGGATAATCAG AAGATAATCTCCAAGCTAGAATCATTGCTGTTATTGAAGGGAGAAGTTGAGTCAATTAAGAAGCAGATCA ACAGGCAAAATATCAGCATATCCACCCTGGAAGGACACCTCTCAAGCATCATGATTGCCATTCCTGGACT TGGGAAGGATCCCAACGACCCCACTGCAGATGTCGAACTCAATCCCGACCTGAAACCCATCATAGGCAGA GATTCAGGCCGAGCACTGGCCGAAGTTCTCAAGAAGCCCGTTGCCAGCCGACAACTCCAGGGAATGACTA ATGGACGGACCAGTTCCAGAGGACAGCTGCTGAAGGAATTTCAACTAAAGCCGATCGGGAAAAAGGTGAG CTCAGCCGTCGGGTTTGTTCCTGACACCGGCCCTGCATCACGCAGTGTAATCCGCTCCATTATAAAATCC AGCCGGCTAGAGGAGGATCGGAAGCGTTACCTGATGACTCTCCTTGATGATATCAAAGGAGCCAACGATC TTGCCAAGTTCCACCAGATGCTGATGAAGATAATAATGAAGTAGCTACAGCTCAACTTACCTGCCAACCC CATGCCAGTCGACCTAATTAGTACAACCTAAATCCATTATAAAAA >NP_056919.1 phosphoprotein [Measles morbillivirus] MAEEQARHVKNGLECIRALKAEPIGSLAVEEAMAAWSEISDNPGQDRATCKEEEAGSSGLSKPCLSAIGS TEGGAPRIRGQGSGESDDDAETLGIPSRNLQASSTGLQCYHVYDHSGEAVKGIQDADSIMVQSGLDGDST LSGGDDESENSDVDIGEPDTEGYAITDRGSAPISMGFRASDVETAEGGEIHELLKLQSRGNNFPKLGKTL NVPPPPNPSRASTSETPIKKGTDARLASFGTEIASLLTGGATQCARKSPSEPSGPGAPAGNVPECVSNAA LIQEWTPESGTTISPRSQNNEEGGDYYDDELFSDVQDIKTALAKIHEDNQKIISKLESLLLLKGEVESIK KQINRQNISISTLEGHLSSIMIAIPGLGKDPNDPTADVELNPDLKPIIGRDSGRALAEVLKKPVASRQLQ GMTNGRTSSRGQLLKEFQLKPIGKKVSSAVGFVPDTGPASRSVIRSIIKSSRLEEDRKRYLMTLLDDIKG ANDLAKFHQMLMKIIMK Protective antigen Lewis rats were immunized with recombinant vaccinia virus (VV) expressing various proteins of measles virus (MV). VVP (Phosphoprotein) -immunized rats were partially protected from MV challenge [Ref1177:Brinckmann et al., 1991]. Brinckmann et al., 1991 journal Brinckmann UG, Bankamp B, Reich A, ter Meulen V, Liebert UG 1991 72 ( Pt 10) 2491-2500 The Journal of general virology Drillien et al., 1988 journal Drillien R, Spehner D, Kirn A, Giraudon P, Buckland R, Wild F, Lecocq JP 1988 85 4 1252-1256 Proceedings of the National Academy of Sciences of the United States of America FDA: Attenuvax website http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm203032.htm FDA: MMR-II website http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm FDA: ProQuad website http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094051.htm Gillet et al., 2009 journal Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A 2009 7 16 BMC medicine Griffin et al., 2008 journal Griffin DE, Pan CH, Moss WJ 2008 13 1352-1370 Frontiers in bioscience : a journal and virtual library GSK: Priorix website http://www.gsk.ca/english/docs-pdf/Priorix_PM_20081103_EN.pdf GSK: Priorix-Tetra website http://www.gsk.ca/english/docs-pdf/Priorix-Tetra_PM_20090908_EN.pdf Martinez et al., 1997 journal Martinez X, Brandt C, Saddallah F, Tougne C, Barrios C, Wild F, Dougan G, Lambert PH, Siegrist CA 1997 94 16 8726-8731 Proceedings of the National Academy of Sciences of the United States of America Pan et al., 2010 journal Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, Lau B, Adams RJ, Polo JM, Griffin DE 2010 84 8 3798-3807 Journal of virology Spreng et al., 2000 journal Spreng S, Gentschev I, Goebel W, Weidinger G, ter Meulen V, Niewiesk S 2000 2 14 1687-1692 Microbes and infection / Institut Pasteur Wiki: Measles website http://en.wikipedia.org/wiki/Measles Yanagi et al., 2006 journal Yanagi Y, Takeda M, Ohno S 2006 87 Pt 10 2767-2779 The Journal of general virology